智通财经APP获悉，心通医疗-B(02160)盈警高开近3%，截至发稿，涨2.4%，报1.28港元，成交额40.58万港元。
消息面上，3月6日，心通医疗-B发布公告，该集团预期2024年取得净亏损约人民币3000万-6000万元，同比减少约87%至94%。公告称，预期亏损减少主要是由于： 经导管主动脉瓣膜植入术产品VitaFlow®及VitaFlow Liberty®和 AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化有序推进，植入量持续增长；VitaFlow Liberty®经导管主动脉瓣膜及可回收输送系统于报告期内获得CE标志，并已在海外17个国家╱地区实现销售，来自海外的收入较2023 年度增长一倍以上。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.